Webinar

Moving Your MetID from Paper to Web

April 26, 2017, 11:00 AM–12:00 PM EST

Want more information about MetaSense? View our first MetaSense Webinar: How to Conquer Your MetID Data

MetID scientists ultimately aim to produce an elucidated biotransformation map with full clarity of the parent compound's metabolic pathway. This information is used by discovery and development groups to understand the metabolic liabilities that can assist in directing the next steps of synthesis. Elucidation of the biotransformation map, however, is a common bottleneck since metabolite identification scientists must deal with disparate data sources and manual workflows for LC/MS data processing and interpretation.

Despite significant instrumental and software advances, reporting remains a manual process. In this webinar you will discover how the MetID reporting processes can be streamlined for reaching short and long-term goals with an easy and interactive solution.

  1. Report in one click
    Move from a tedious manual process to a semi-automated and customizable single homogeneous environment.
  2. Data on demand
    Skip the hassle of looking through multiple physical documents, with a web portal that allows you to search and share your data in real-time.
  3. Simple deployment
    Minimize IT overhead with a simple server installation and java based access.

Learning Objectives

An introduction to a new software solution to support metabolite identification by LC/MS with advanced reporting capabilities.

Intended Audience

IT and informatics personnel, business case manager, director, manager or senior scientist that supports metID reporting:

  • Analytical/MetID group
  • Medicinal/Synthetic chemistry
  • MS/Analytical labs

Consumers of metID reports that are a director, manager, senior scientist or synthetic chemist:

  • Synthetic group
  • Medicinal chemistry


Presented By

Richard Lee
Richard Lee (Solutions Manager, Metabolite Identification & Characterization)
Richard obtained his Ph.D. from McMaster University in Canada, where his area of study focused on strategies for metabolite identification and metabolomics studies. From McMaster, he moved on as a Scientist at the Centre of Probe Development and Commercialization in Hamilton, Ontario, which developed radiopharmaceuticals as imaging agents and therapeutics for oncology. He has been with ACD/Labs for the past 4 years and has been responsible for the development of the MetaSense solution since its inception.